A view of Moderna headquarters on May 08, 2020 in Cambridge, Massachusetts. Moderna was given FDA approval to continue to phase 2 of Coronavirus (COVID-19) vaccine trials with 600 participants. (Photo by Maddie Meyer/Getty Images) CAMBRIDGE, Mass - Drugmaker Moderna found promising results in Phase 1 of its COVID-19 vaccine trial.
Eight of the patients who received two doses of mRNA-1273 — one at 25 micrograms and the other at 100 — developed neutralizing antibodies similar to the ones developed by people who’ve recovered from the virus. RELATED: CoronavirusNOW.com, FOX launches national hub for COVID-19 news and updates "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the